| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.775 | 0.003 | 0.775 | ErbB-1 antagonist | 0.775 0.003 DBMET00935 | ||
| 0.752 | 0.004 | 0.763 | Epidermal growth factor antagonist | 0.763 0.004 DBMET00935 | DBMET00935 | |
| 0.748 | 0.005 | 0.75 | Growth factor antagonist | 0.75 0.005 DBMET00935 | DBMET00935 | |
| 0.742 | 0.004 | 0.766 | Epidermal growth factor receptor kinase inhibitor | 0.766 0.004 DBMET00935 | DBMET00935 | |
| 0.663 | 0.004 | 0.711 | Vascular endothelial growth factor 3 antagonist | 0.711 0.004 DBMET00935 | DBMET00935 | |
| 0.649 | 0.002 | 0.649 | EphB4 antagonist | 0.573 0.002 DBMET00935 | ||
| 0.65 | 0.005 | 0.662 | Vascular endothelial growth factor antagonist | 0.662 0.005 DBMET00935 | DBMET00935 | |
| 0.638 | 0.005 | 0.65 | Vascular endothelial growth factor 2 antagonist | 0.65 0.005 DBMET00935 | DBMET00935 | |
| 0.601 | 0.016 | 0.601 | Angiogenesis inhibitor | 0.601 0.016 DBMET00935 | ||
| 0.528 | 0.005 | 0.528 | DNA methylase inhibitor | 0.457 0.008 DBMET00935 | ||
| 0.497 | 0.005 | 0.497 | MAP kinase kinase 2 inhibitor | 0.496 0.005 DBMET00935 | ||
| 0.494 | 0.004 | 0.505 | Ephrin antagonist | 0.505 0.004 DBMET00935 | DBMET00935 | |
| 0.472 | 0.004 | 0.512 | ErbB-2 antagonist | 0.512 0.004 DBMET00935 | DBMET00935 | |
| 0.429 | 0.005 | 0.437 | Vascular endothelial growth factor 1 antagonist | 0.437 0.005 DBMET00935 | DBMET00935 | |
| 0.424 | 0.007 | 0.424 | DNA methyltransferase I inhibitor | 0.35 0.014 DBMET00935 | ||
| 0.385 | 0.003 | 0.392 | EphA2 antagonist | 0.392 0.003 DBMET00935 | DBMET00935 | |
| 0.373 | 0.012 | 0.373 | RET inhibitor | 0.372 0.012 DBMET00935 | ||
| 0.359 | 0.005 | 0.359 | MAP kinase kinase inhibitor | 0.349 0.005 DBMET00935 | ||
| 0.355 | 0.019 | 0.368 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.368 0.017 DBMET00935 | DBMET00935 | |
| 0.335 | 0.037 | 0.335 | Tyrosine kinase inhibitor | 0.324 0.039 DBMET00935 | ||
| 0.307 | 0.011 | 0.307 | Platelet activating factor beta antagonist | 0.289 0.012 DBMET00935 | ||
| 0.301 | 0.014 | 0.318 | I kappa B kinase epsilon inhibitor | 0.318 0.009 DBMET00935 | DBMET00935 | |
| 0.289 | 0.005 | 0.289 | ErbB-4 antagonist | 0.265 0.007 DBMET00935 | ||
| 0.301 | 0.019 | 0.306 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.306 0.018 DBMET00935 | DBMET00935 | |
| 0.287 | 0.013 | 0.302 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.302 0.012 DBMET00935 | DBMET00935 | |
| 0.285 | 0.02 | 0.285 | c-Src kinase inhibitor | 0.264 0.023 DBMET00935 | ||
| 0.27 | 0.005 | 0.27 | Insulin growth factor antagonist | 0.24 0.006 DBMET00935 | ||
| 0.288 | 0.028 | 0.288 | Src kinase inhibitor | 0.277 0.03 DBMET00935 | ||
| 0.264 | 0.005 | 0.264 | Insulin like growth factor 1 antagonist | 0.234 0.006 DBMET00935 | ||
| 0.296 | 0.039 | 0.336 | Clk dual-specificity kinase inhibitor | 0.336 0.03 DBMET00935 | DBMET00935 | |
| 0.245 | 0.019 | 0.255 | CDC-like kinase 1 inhibitor | 0.255 0.017 DBMET00935 | DBMET00935 | |
| 0.27 | 0.044 | 0.311 | Platelet aggregation inhibitor | 0.311 0.033 DBMET00935 | DBMET00935 | |
| 0.241 | 0.018 | 0.241 | Platelet activating factor antagonist | 0.224 0.021 DBMET00935 | ||
| 0.358 | 0.139 | 0.399 | Caspase 9 stimulant | 0.399 0.111 DBMET00935 | DBMET00935 | |
| 0.212 | 0.005 | 0.212 | Fibroblast growth factor 2 antagonist | 0.16 0.009 DBMET00935 | ||
| 0.213 | 0.008 | 0.213 | ErbB-3 antagonist | 0.197 0.01 DBMET00935 | ||
| 0.259 | 0.068 | 0.291 | Dyrk kinase inhibitor | 0.291 0.056 DBMET00935 | DBMET00935 | |
| 0.217 | 0.027 | 0.24 | Aurora-B kinase inhibitor | 0.24 0.023 DBMET00935 | DBMET00935 | |
| 0.218 | 0.03 | 0.222 | Activin receptor-like kinase 2 inhibitor | 0.222 0.028 DBMET00935 | DBMET00935 | |
| 0.254 | 0.066 | 0.282 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.282 0.055 DBMET00935 | DBMET00935 | |
| 0.2 | 0.017 | 0.2 | Platelet activating factor alpha antagonist | 0.194 0.018 DBMET00935 | ||
| 0.188 | 0.006 | 0.188 | MAP kinase kinase 1 inhibitor | 0.178 0.008 DBMET00935 | ||
| 0.236 | 0.065 | 0.236 | EphB2 antagonist | 0.235 0.065 DBMET00935 | ||
| 0.201 | 0.031 | 0.21 | MAP kinase kinase 5 inhibitor | 0.21 0.023 DBMET00935 | DBMET00935 | |
| 0.191 | 0.024 | 0.191 | Granulocyte macrophage colony stimulating factor antagonist | 0.165 0.031 DBMET00935 | ||
| 0.207 | 0.043 | 0.207 | Protein-tyrosine kinase Lyn inhibitor | 0.207 0.043 DBMET00935 | ||
| 0.22 | 0.058 | 0.263 | CDC-like kinase 4 inhibitor | 0.263 0.042 DBMET00935 | DBMET00935 | |
| 0.183 | 0.026 | 0.221 | Cyclin-dependent kinase 9 inhibitor | 0.221 0.018 DBMET00935 | DBMET00935 | |
| 0.172 | 0.024 | 0.172 | Fibroblast growth factor 1 antagonist | 0.148 0.032 DBMET00935 | ||
| 0.19 | 0.045 | 0.19 | Lck kinase inhibitor | 0.188 0.046 DBMET00935 | ||
| 0.191 | 0.047 | 0.215 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.215 0.036 DBMET00935 | DBMET00935 | |
| 0.156 | 0.014 | 0.156 | Polo-like kinase-1 inhibitor | 0.104 0.041 DBMET00935 | ||
| 0.209 | 0.079 | 0.209 | Antimitotic | 0.184 0.094 DBMET00935 | ||
| 0.147 | 0.02 | 0.147 | Platelet growth factor antagonist | 0.131 0.025 DBMET00935 | ||
| 0.295 | 0.185 | 0.295 | MAP kinase 1 inhibitor | |||
| 0.152 | 0.046 | 0.152 | TRKB antagonist | 0.145 0.05 DBMET00935 | ||
| 0.126 | 0.024 | 0.126 | Bcr-Abl kinase inhibitor | 0.091 0.05 DBMET00935 | ||
| 0.158 | 0.056 | 0.178 | MAP kinase 3 inhibitor | 0.178 0.036 DBMET00935 | DBMET00935 | |
| 0.15 | 0.048 | 0.15 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.145 0.05 DBMET00935 | ||
| 0.127 | 0.025 | 0.127 | AXL receptor tyrosine kinase inhibitor | 0.122 0.026 DBMET00935 | ||
| 0.149 | 0.048 | 0.149 | Abl kinase inhibitor | 0.145 0.05 DBMET00935 | ||
| 0.202 | 0.101 | 0.217 | MAP-kinase-activated kinase 5 inhibitor | 0.217 0.084 DBMET00935 | DBMET00935 | |
| 0.194 | 0.095 | 0.203 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.203 0.088 DBMET00935 | DBMET00935 | |
| 0.125 | 0.029 | 0.125 | Leucine-rich repeat kinase 2 inhibitor | 0.111 0.036 DBMET00935 | ||
| 0.114 | 0.021 | 0.135 | Raf kinase C inhibitor | 0.135 0.017 DBMET00935 | DBMET00935 | |
| 0.15 | 0.061 | 0.16 | MAP3K9 inhibitor | 0.16 0.046 DBMET00935 | DBMET00935 | |
| 0.181 | 0.093 | 0.181 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.177 0.097 DBMET00935 | ||
| 0.126 | 0.038 | 0.126 | Insulin receptor antagonist | 0.095 0.068 DBMET00935 | ||
| 0.117 | 0.031 | 0.117 | TIE-2 antagonist | 0.115 0.032 DBMET00935 | ||
| 0.116 | 0.032 | 0.116 | TIE antagonist | 0.114 0.033 DBMET00935 | ||
| 0.133 | 0.05 | 0.133 | 5 Hydroxytryptamine 2B antagonist | 0.106 0.076 DBMET00935 | ||
| 0.093 | 0.014 | 0.093 | MAP kinase 7 inhibitor | 0.082 0.036 DBMET00935 | ||
| 0.22 | 0.143 | 0.22 | Caspase 3 stimulant | 0.216 0.148 DBMET00935 | ||
| 0.214 | 0.142 | 0.214 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.185 0.176 DBMET00935 | ||
| 0.086 | 0.017 | 0.094 | Cyclin B1 inhibitor | 0.094 0.013 DBMET00935 | DBMET00935 | |
| 0.151 | 0.083 | 0.151 | Polo-like kinase-3 inhibitor | 0.132 0.106 DBMET00935 | ||
| 0.106 | 0.038 | 0.106 | ALK inhibitor | 0.1 0.041 DBMET00935 | ||
| 0.081 | 0.016 | 0.085 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.085 0.014 DBMET00935 | DBMET00935 | |
| 0.135 | 0.07 | 0.135 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.126 0.077 DBMET00935 | ||
| 0.119 | 0.057 | 0.119 | Polo-like kinase-4 inhibitor | 0.101 0.076 DBMET00935 | ||
| 0.109 | 0.047 | 0.116 | Breast cancer-resistant protein inhibitor | 0.116 0.042 DBMET00935 | DBMET00935 | |
| 0.078 | 0.016 | 0.086 | Cyclin B2 inhibitor | 0.086 0.012 DBMET00935 | DBMET00935 | |
| 0.106 | 0.046 | 0.106 | Hepatocyte growth factor antagonist | 0.106 0.045 DBMET00935 | ||
| 0.092 | 0.033 | 0.092 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.089 0.035 DBMET00935 | ||
| 0.112 | 0.054 | 0.112 | CDC-like kinase 3 inhibitor | 0.103 0.072 DBMET00935 | ||
| 0.147 | 0.09 | 0.147 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.132 0.103 DBMET00935 | ||
| 0.093 | 0.037 | 0.093 | Fibroblast growth factor 3 antagonist | 0.073 0.06 DBMET00935 | ||
| 0.085 | 0.029 | 0.085 | ZAP-70 protein tyrosine kinase inhibitor | 0.083 0.031 DBMET00935 | ||
| 0.072 | 0.02 | 0.081 | Cyclin B inhibitor | 0.081 0.015 DBMET00935 | DBMET00935 | |
| 0.131 | 0.081 | 0.141 | Aurora-C kinase inhibitor | 0.141 0.064 DBMET00935 | DBMET00935 | |
| 0.162 | 0.113 | 0.193 | Focal adhesion kinase 2 inhibitor | 0.193 0.075 DBMET00935 | DBMET00935 | |
| 0.1 | 0.053 | 0.112 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.112 0.044 DBMET00935 | DBMET00935 | |
| 0.115 | 0.068 | 0.135 | Interleukin 8 antagonist | 0.135 0.045 DBMET00935 | DBMET00935 | |
| 0.084 | 0.044 | 0.091 | Phosphodiesterase 4D inhibitor | 0.091 0.041 DBMET00935 | DBMET00935 | |
| 0.106 | 0.068 | 0.106 | Multidrug resistance-associated protein 1 inhibitor | 0.096 0.085 DBMET00935 | ||
| 0.054 | 0.021 | 0.075 | Fructose-1,6-bisphosphatase inhibitor | 0.075 0.01 DBMET00935 | DBMET00935 | |
| 0.099 | 0.066 | 0.1 | Aurora-A kinase inhibitor | 0.1 0.066 DBMET00935 | DBMET00935 | |
| 0.199 | 0.168 | 0.225 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.225 0.105 DBMET00935 | DBMET00935 | |
| 0.077 | 0.047 | 0.087 | Raf kinase inhibitor | 0.087 0.04 DBMET00935 | DBMET00935 | |
| 0.064 | 0.037 | 0.064 | Phosphodiesterase 1B inhibitor | |||
| 0.079 | 0.053 | 0.079 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.079 0.054 DBMET00935 | ||
| 0.095 | 0.07 | 0.115 | Cyclin-dependent kinase 1 inhibitor | 0.115 0.057 DBMET00935 | DBMET00935 | |
| 0.082 | 0.058 | 0.082 | T cell inhibitor | 0.08 0.067 DBMET00935 | ||
| 0.07 | 0.047 | 0.077 | CDK1/cyclin B1 inhibitor | 0.077 0.041 DBMET00935 | DBMET00935 | |
| 0.154 | 0.132 | 0.154 | Growth factor agonist | |||
| 0.061 | 0.04 | 0.073 | Raf kinase B inhibitor | 0.073 0.032 DBMET00935 | DBMET00935 | |
| 0.111 | 0.091 | 0.111 | Phosphodiesterase inhibitor | 0.109 0.094 DBMET00935 | ||
| 0.124 | 0.105 | 0.129 | Insulin secretagoues | 0.129 0.099 DBMET00935 | DBMET00935 | |
| 0.042 | 0.023 | 0.042 | G protein-coupled receptor agonist | 0.04 0.024 DBMET00935 | ||
| 0.074 | 0.056 | 0.074 | Focal adhesion kinase 1 inhibitor | |||
| 0.058 | 0.04 | 0.058 | Fibroblast growth factor 4 antagonist | |||
| 0.07 | 0.057 | 0.07 | Alpha 2a adrenoreceptor antagonist | 0.065 0.064 DBMET00935 | ||
| 0.06 | 0.047 | 0.06 | Cyclin A2 inhibitor | 0.06 0.047 DBMET00935 | ||
| 0.056 | 0.048 | 0.056 | Cyclin A inhibitor | 0.056 0.048 DBMET00935 | ||
| 0.033 | 0.026 | 0.033 | Glucose-dependent insulinotropic receptor agonist | 0.032 0.028 DBMET00935 | ||
| 0.055 | 0.049 | 0.069 | Alpha 2 adrenoreceptor agonist | 0.069 0.033 DBMET00935 | DBMET00935 | |
| 0.083 | 0.077 | 0.089 | CDK2/cyclin A inhibitor | 0.089 0.068 DBMET00935 | DBMET00935 | |
| 0.081 | 0.075 | 0.081 | Phosphodiesterase I inhibitor | |||
| 0.044 | 0.039 | 0.049 | CC chemokine 4 receptor antagonist | 0.049 0.028 DBMET00935 | DBMET00935 | |
| 0.121 | 0.118 | 0.159 | CDC-like kinase 2 inhibitor | 0.159 0.087 DBMET00935 | DBMET00935 | |
| 0.129 | 0.129 | 0.17 | Tumour necrosis factor antagonist | 0.17 0.077 DBMET00935 | DBMET00935 | |
| 0.123 | 0.123 | 0.151 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.151 0.094 DBMET00935 | DBMET00935 | |
| 0.081 | 0.082 | 0.138 | Check point kinase 2 inhibitor | 0.138 0.036 DBMET00935 | DBMET00935 | |
| 0.057 | 0.062 | 0.059 | Cyclin B3 inhibitor | 0.059 0.058 DBMET00935 | DBMET00935 | |
| 0.051 | 0.057 | 0.056 | CDK1/cyclin B inhibitor | 0.056 0.05 DBMET00935 | DBMET00935 | |
| 0.082 | 0.098 | 0.119 | Protein kinase (CK2) alpha inhibitor | 0.119 0.063 DBMET00935 | DBMET00935 | |
| 0.053 | 0.069 | 0.063 | Phosphodiesterase 4B inhibitor | 0.063 0.052 DBMET00935 | DBMET00935 | |
| 0.085 | 0.104 | 0.092 | Interleukin 1b antagonist | 0.092 0.091 DBMET00935 | DBMET00935 | |
| 0.071 | 0.097 | 0.104 | Protein kinase (CK2) inhibitor | 0.104 0.061 DBMET00935 | DBMET00935 | |
| 0.06 | 0.118 | 0.087 | Pim-1 kinase inhibitor | 0.087 0.071 DBMET00935 | DBMET00935 | |
| 0.104 | 0.17 | 0.164 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.164 0.107 DBMET00935 | DBMET00935 | |
| 0.111 | 0.189 | 0.133 | MAP kinase kinase 4 inhibitor | 0.133 0.104 DBMET00935 | DBMET00935 | |
| 0.057 | 0.156 | 0.073 | MAP kinase kinase 7 inhibitor | 0.073 0.07 DBMET00935 | DBMET00935 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |